IBUPROFEN TABLET
Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
Produkta apraksts
(SPC)
26-02-2020
Daži šī produkta dokumenti pašlaik nav pieejami. Varat nosūtīt pieprasījumu mūsu klientu apkalpošanas dienestam, un mēs jums paziņosim, tiklīdz mēs tos varēsim iegūt.
Nosūtīt pieprasījumu.
Nosūtīt pieprasījumu.
Aktīvā sastāvdaļa:
IBUPROFEN
Pieejams no:
ANGITA PHARMA INC.
ATĶ kods:
M01AE01
SNN (starptautisko nepatentēto nosaukumu):
IBUPROFEN
Deva:
200MG
Zāļu forma:
TABLET
Kompozīcija:
IBUPROFEN 200MG
Ievadīšanas:
ORAL
Vienības iepakojumā:
100
Receptes veids:
OTC
Ārstniecības joma:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produktu pārskats:
Active ingredient group (AIG) number: 0108883004; AHFS:
Autorizācija statuss:
APPROVED
Autorizācija datums:
2020-04-23
Produkta apraksts
_Page 1 / 40_
PRODUCT MONOGRAPH
IBUPROFEN
Ibuprofen Tablets USP
200mg and 400 mg
Non-Steroidal Anti-inflammatory Drug
Analgesic, Antipyretic Agent
Angita Pharma Inc.
1310 Nobel Street,
Boucherville,
Québec Canada, J4B 5H3
Date of Preparation: February 26, 2020
Control # 236574
_Page 2 / 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINCAL USE
...........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
9
DRUG INTERACTIONS
..............................................................................................................
12
DOSAGE AND ADMINISTRATION
..........................................................................................
15
OVERDOSAGE
..................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
16
STORAGE AND STABILITY
......................................................................................................
17
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 18
PART II: SCIENTIFIC INFORMATION
................................................................................
19
PHARMACEUTICAL INFORMATION
..................
Izlasiet visu dokumentu
